Entelos, Inc. (LSE:ENTL) a leading life sciences company building predictive computer models of human physiology and "virtual patients" for drug discovery and development, announced today that Eli Lilly and Company (“Lilly”) has signed an agreement with Entelos to conduct in silico research in the field of diabetes using the Entelos® Metabolism PhysioLab® platform. Financial terms were not disclosed.

The Entelos Metabolism PhysioLab platform is an innovative and predictive computer model that simulates diabetic patients and can accurately predict the effects of drugs, changes in diet and exercise, and other interventions. The platform has already been used successfully with other pharmaceutical partners to select targets and compounds, find the best doses for patients, and support clinical trial design.

“We are pleased to be conducting in silico research for Lilly, who is a long time customer of Entelos’ predictive toxicology systems and other information products,” commented James Karis, President and CEO of Entelos. “We believe that our Metabolism platform enables more rapid assessment, evaluation, and testing of complex therapies to help accelerate R&D and we look forward to supporting Lilly’s programs.”

  www.entelos.com